|Bid||6.15 x 3000|
|Ask||6.32 x 2200|
|Day's Range||5.89 - 6.17|
|52 Week Range||5.61 - 48.05|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 09, 2022 - Mar 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.96|
If you have the guts for it, buying a stock that other investors scorn can be a great way to pick up shares of companies with good bones at a steep bargain. If fortunes turn, you'll get to be the proud contrarian who saw the true potential of the business as a bonus -- assuming that its fortunes do turn. After crashing by more than 80% over the last year, it isn't a stretch to say that GoodRx's (NASDAQ: GDRX) stock is a beaten-down shadow of its former self.
"In terms of risk factors that we continue to monitor, the overall global consumer landscape remains our top focus," a Goldman Sachs analyst wrote.
Today we will run through one way of estimating the intrinsic value of GoodRx Holdings, Inc. ( NASDAQ:GDRX ) by taking...